WHO Collaborating Centre for the Epidemiology, Detection and Control of Cystic and Alveolar Echinococcosis, Department of Infectious Diseases, Istituto Superiore Di Sanità, Rome, Italy.
European Reference Laboratory for Parasites, Department of Infectious Diseases, Istituto Superiore Di Sanità, Rome, Italy.
Parasit Vectors. 2022 Mar 28;15(1):109. doi: 10.1186/s13071-022-05197-8.
This study aimed to fill a gap of knowledge by providing a quantitative measure of molecularly identified species and genotypes belonging to Echinococcus granulosus sensu lato (s.l.) causing human cystic echinococcosis (CE) in Europe during the period 2000-2021. As these species and genotypes are characterized by genetic, animal host and geographical differences, studying the E. granulosus s.l. complex is epidemiologically relevant.
A systematic review (SR) was conducted on the basis of both scientific and grey literature considering primary studies between 2000 and 2021 in four databases. From a total of 1643 scientific papers, 51 records were included in the SR. The main inclusion criterion for this study was the molecular confirmation of E. granulosus s.l. at the genotype/species level as a causative agent of human CE cases in selected European countries.
Relevant data were obtained from 29 out of 39 eligible European countries. This SR identified 599 human molecularly confirmed echinococcal cysts: 460 (76.8%) identified as E. granulosus sensu stricto (s.s.), 130 (21.7%) as E. canadensis cluster (G6/7 and G10), 7 (1.2%) as E. ortleppi (G5), and 2 as E. vogeli (0.3%). Three geographical hotspots of human CE caused by different species of the E. granulosus s.l. complex were identified: (1) E. granulosus s.s. in Southern and South-eastern Europe (European-Mediterranean and Balkan countries); (2) E. canadensis (G6/7) in Central and Eastern Europe; (3) E. ortleppi in Central and Western Europe. This SR also identified data gaps that prevented a better definition of the geographical distribution of the Echinococcus granulosus s.l. species complex in Europe: western Balkan countries, part of Central Europe, and Baltic countries.
These results mandate longitudinal, multi-centre, intersectoral and transdisciplinary studies which consider both molecular and clinical epidemiology in animals and humans. Such studies would be valuable for a better understanding of the transmission of the E. granulosus s.l. species complex and their potential clinical impact on humans.
本研究旨在填补知识空白,提供 2000-2021 年期间欧洲导致人类囊性包虫病(CE)的分子鉴定的细粒棘球蚴属(Echinococcus granulosus sensu lato,s.l.)物种和基因型的定量测量。由于这些物种和基因型具有遗传、动物宿主和地理差异的特点,因此研究细粒棘球蚴 s.l. 复合物在流行病学上具有相关性。
基于科学和灰色文献,对 2000 年至 2021 年期间的原始研究进行了系统评价(SR),并在四个数据库中进行了研究。从总共 1643 篇科学论文中,SR 纳入了 51 篇记录。本研究的主要纳入标准是在选定的欧洲国家,通过分子方法确认细粒棘球蚴 s.l. 是人类 CE 病例的病原体。
从 39 个符合条件的欧洲国家中获得了相关数据。本 SR 鉴定了 599 例人类分子确认的棘球蚴囊肿:460 例(76.8%)鉴定为细粒棘球蚴 s.s.,130 例(21.7%)鉴定为加拿大棘球蚴群(G6/7 和 G10),7 例(1.2%)鉴定为ORTLEPPI 棘球蚴(G5),2 例鉴定为 vogeli 棘球蚴(0.3%)。鉴定出人类 CE 的三个地理热点是由细粒棘球蚴 s.l. 复合物的不同物种引起的:(1)欧洲地中海和巴尔干国家的细粒棘球蚴 s.s.;(2)中欧的加拿大棘球蚴(G6/7);(3)西欧的ORTLEPPI 棘球蚴。本 SR 还发现了数据空白,这些空白阻碍了更好地确定欧洲细粒棘球蚴 s.l. 种复合物的地理分布:西巴尔干国家、中欧部分地区和波罗的海国家。
这些结果要求进行纵向、多中心、跨部门和跨学科研究,同时考虑动物和人类的分子和临床流行病学。这些研究对于更好地了解细粒棘球蚴 s.l. 种复合物的传播及其对人类的潜在临床影响将具有重要价值。